This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BioMarin Stops Voxzogo Development for Noonan Syndrome

BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.

10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.

Ascendis Pharma shares are trading lower after the company announced it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. Also, Raymond James downgraded the stock from Strong Buy to Outperform.

HSBC Downgrades Banco Santander to Hold, Lowers Price Target to $6.2

HSBC analyst Carlos Gomez-Lopez downgrades Banco Santander (NYSE:BSBR) from Buy to Hold and lowers the price target from $7.2 to $6.2.

This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.